- Home
- LEXX vs GROW Comparison
LEXX vs GROW Comparison
Compare LEXX & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- GROW
- Stock Information
- Founded
- LEXX 2004
- GROW 1968
- Country
- LEXX Canada
- GROW United States
- Employees
- LEXX N/A
- GROW N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- GROW Investment Managers
- Sector
- LEXX Health Care
- GROW Finance
- Exchange
- LEXX Nasdaq
- GROW Nasdaq
- Market Cap
- LEXX 39.1M
- GROW 32.9M
- IPO Year
- LEXX N/A
- GROW N/A
- Fundamental
- Price
- LEXX $1.45
- GROW $2.43
- Analyst Decision
- LEXX Strong Buy
- GROW
- Analyst Count
- LEXX 2
- GROW 0
- Target Price
- LEXX $9.50
- GROW N/A
- AVG Volume (30 Days)
- LEXX 110.6K
- GROW 30.6K
- Earning Date
- LEXX 04-08-2025
- GROW 02-12-2025
- Dividend Yield
- LEXX N/A
- GROW 3.71%
- EPS Growth
- LEXX N/A
- GROW N/A
- EPS
- LEXX N/A
- GROW 0.04
- Revenue
- LEXX $496,923.00
- GROW $9,421,000.00
- Revenue This Year
- LEXX $30.72
- GROW N/A
- Revenue Next Year
- LEXX $31.85
- GROW N/A
- P/E Ratio
- LEXX N/A
- GROW $65.73
- Revenue Growth
- LEXX 77.63
- GROW N/A
- 52 Week Low
- LEXX $1.38
- GROW $2.38
- 52 Week High
- LEXX $6.85
- GROW $2.95
- Technical
- Relative Strength Index (RSI)
- LEXX 33.85
- GROW 46.23
- Support Level
- LEXX $1.38
- GROW $2.43
- Resistance Level
- LEXX $1.72
- GROW $2.46
- Average True Range (ATR)
- LEXX 0.12
- GROW 0.04
- MACD
- LEXX -0.01
- GROW -0.00
- Stochastic Oscillator
- LEXX 12.85
- GROW 7.14
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.